Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SER-287 in mild-to-moderate ulcerative colitis
NCT02618187Phase 1Completed
- Sponsor
- Seres Therapeutics
- Start
- Jan 2016
- Primary completion
- Dec 2017
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SER287 in ulcerative colitis (UC) (4 arms), sponsored by Seres Therapeutics. Primary endpoints: Safety and Tolerability of SER-287 at Day 246, Composition of the Intestinal Microbiome at 8 weeks and 1 more. Started Jan 2016; status: completed.
02
Drugs
SER287
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02618187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02618187.